Norovirus vaccines and potential antinorovirus drugs: Recent advances and future perspectives

Future Virology

Volumn 10, Issue 7, 2015, Pages 899-913

  Kocher, Jacob ^a   Yuan, Lijuan ^a  

^a CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

Author keywords

antivirals; human norovirus; vaccines

Indexed keywords

ANTIVIRUS AGENT; NOROVIRUS VACCINE; P PARTICLE VACCINE; UNCLASSIFIED DRUG; VECTORED VLP VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

B LYMPHOCYTE; CELL CULTURE; ECONOMIC ASPECT; GENOMICS; HUMAN; IMMUNITY; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE;

ANIMALIA; MIRIDAE; NOROVIRUS;

EID: 84938701638     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.15.57     Document Type: Review

References (129)

1. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 346(2), 312-323 (2006).
2. Mesquita JR, Costantini VP, Cannon JL, Lin SC, Nascimento MS, Vinje J. Presence of antibodies against genogroup VI norovirus in humans. Virol. J. 10, 176 (2013).
3. Chen SY, Chiu CH. Worldwide molecular epidemiology of norovirus infection. Paediatr. Int. Child Health 32(3), 128-131 (2012).
4. Hall AJ, Lopman BA, Payne DC et al. Norovirus disease in the United States. Emerg. Infect. Dis. 19(8), 1198-1205 (2013).
5. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14(8), 1224-1231 (2008).
6. Lee RM, Lessler J, Lee RA et al. Incubation periods of viral gastroenteritis: a systematic review. BMC Infect. Dis. 13, 446 (2013).
7. Lopman BA, Reacher MH, Vipond IB, Sarangi J, Brown DW. Clinical manifestation of norovirus gastroenteritis in health care settings. Clin. Infect. Dis. 39(3), 318-324 (2004).
8. Li J, Predmore A, Divers E, Lou F. New interventions against human norovirus: progress, opportunities, and challenges. Annu. Rev. Food Sci. Technol. 3, 331-352 (2012).
9. Koopmans M. Progress in understanding norovirus epidemiology. Curr. Opin. Infect. Dis. 21(5), 544-552 (2008).
10. Verani M, Bigazzi R, Carducci A. Viral contamination of aerosol and surfaces through toilet use in health care and other settings. Am. J. Infect. Control 42(7), 758-762 (2014).
11. Belliot G, Lopman BA, Ambert-Balay K, Pothier P. The burden of norovirus gastroenteritis: an important foodborne and healthcare-related infection. Clin. Microbiol. Infect. 20(8), 724-730 (2014).
12. Fankem SL, Boone SA, Gaither M, Gerba CP. Outbreak of norovirus illness in a college summer camp: impact of cleaning on occurrence of norovirus on fomites. J. Environ. Health 76(8), 20-26 (2014).
13. Ahmed SM, Hall AJ, Robinson AE et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect. Dis. 14(8), 725-730 (2014).
14. Ramani S, Atmar RL, Estes MK. Epidemiology of human noroviruses and updates on vaccine development. Curr. Opin. Gastroenterol. 30(1), 25-33 (2014).
15. Becker-Dreps S, Bucardo F, Vilchez S et al. Etiology of childhood diarrhea after rotavirus vaccine introduction: a prospective, population-based study in Nicaragua. Pediatr. Infect. Dis. J. 33(11), 1156-1163 (2014).
16. Karve S, Krishnarajah G, Korsnes JS, Cassidy A, Candrilli SD. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Hum. Vaccin. Immunother. 10(6), 1544-1556 (2014).
17. Hoffmann S, Batz MB, Morris JG Jr. Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens. J. Food Prot. 75(7), 1292-1302 (2012).
18. Bernard H, Werber D, Hohle M. Estimating the under-reporting of norovirus illness in Germany utilizing enhanced awareness of diarrhoea during a large outbreak of Shiga toxin-producing E. coli o104:H4 in 2011-a time series analysis. BMC Infect. Dis. 14, 116 (2014).
19. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine 30(49), 7097-7104 (2012).
20. Jiang X, Wang M, Wang K, Estes MK. Sequence and genomic organization of Norwalk virus. Virology 195(1), 51-61 (1993).
21. Mcfadden N, Bailey D, Carrara G et al. Norovirus regulation of the innate immune response and apoptosis occurs via the product of the alternative open reading frame 4. PLoS Pathog. 7(12), e1002413 (2011).
22. Clarke IN, Lambden PR. Organization and expression of calcivirus genes. J. Infect. Dis. 181(Suppl. 2), S309-S316 (2000).
23. Sosnovtsev SV, Belliot G, Chang KO et al. Cleavage map and proteolytic processing of the murine norovirus nonstructural polyprotein in infected cells. J. Virol. 80(16), 7816-7831 (2006).
24. Belliot G, Sosnovtsev SV, Mitra T, Hammer C, Garfield M, Green KY. In vitro proteolytic processing of the MD145 norovirus ORF1 nonstructural polyprotein yields stable precursors and products similar to those detected in calicivirus-infected cells. J. Virol. 77(20), 10957-10974 (2003).
25. Thorne LG, Goodfellow IG. Norovirus gene expression and replication. J. Gen. Virol. 95(Pt 2), 278-291 (2014).
26. Karst SM, Wobus CE. A working model of how noroviruses infect the intestine. PLoS Pathog. 11(2), e1004626 (2015).
27. Fernandez-Vega V, Sosnovtsev SV, Belliot G et al. Norwalk virus n-terminal nonstructural protein is associated with disassembly of the golgi complex in transfected cells. J. Virol. 78(9), 4827-4837 (2004).
28. Pfister T, Wimmer E. Polypeptide p41 of a Norwalk-like virus is a nucleic acidindependent nucleoside triphosphatase. J. Virol. 75(4), 1611-1619 (2001).
29. Sharp TM, Guix S, Katayama K, Crawford SE, Estes MK. Inhibition of cellular protein secretion by Norwalk virus nonstructural protein p22 requires a mimic of an endoplasmic reticulum export signal. PLoS ONE 5(10), e13130 (2010).
30. Goodfellow I. The genome-linked protein VPg of vertebrate viruses: a multifaceted protein. Curr. Opin. Virol. 1(5), 355-362 (2011).
31. Daughenbaugh KF, Fraser CS, Hershey JW, Hardy ME. The genome-linked protein VPG of the Norwalk virus binds EIF3, suggesting its role in translation initiation complex recruitment. EMBO J. 22(11), 2852-2859 (2003).
32. Royall E, Doyle N, Abdul-Wahab A et al. Murine norovirus 1 (MNV1) replication induces translational control of the host by regulating EIF4e activity during infection. J. Biol. Chem. 290(8), 4748-4758 (2015).
33. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science 286(5438), 287-290 (1999).
34. Glass PJ, White LJ, Ball JM, Leparc-Goffart I, Hardy ME, Estes MK. Norwalk virus open reading frame 3 encodes a minor structural protein. J. Virol. 74(14), 6581-6591 (2000).
35. Prasad BV, Rothnagel R, Jiang X, Estes MK. Three-dimensional structure of baculovirusexpressed Norwalk virus capsids. J. Virol. 68(8), 5117-5125 (1994).
36. Vongpunsawad S, Venkataram Prasad BV, Estes MK. Norwalk virus minor capsid protein VP2 associates within the VP1 shell domain. J. Virol. 87(9), 4818-4825 (2013).
37. Lin Y, Fengling L, Lianzhu W, Yuxiu Z, Yanhua J. Function of VP2 protein in the stability of the secondary structure of virus-like particles of genogroup II norovirus at different ph levels: function of VP2 protein in the stability of NoV VLPs. J. Microbiol. 52(11), 970-975 (2014).
38. Teunis PF, Moe CL, Liu P et al. Norwalk virus: How infectious is it? J. Med. Virol. 80(8), 1468-1476 (2008).
39. Tan M, Jiang X. Histo-blood group antigens: a common niche for norovirus and rotavirus. Expert Rev. Mol. Med. 16, e5 (2014).
40. Marionneau S, Cailleau-Thomas A, Rocher J et al. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie 83(7), 565-573 (2001).
41. Lindesmith L, Moe C, Marionneau S et al. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9(5), 548-553 (2003).
42. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis. 185(9), 1335-1337 (2002).
43. Trang NV, Vu HT, Le NT, Huang P, Jiang X, Anh DD. Association between norovirus and rotavirus infection and histo-blood group antigen types in Vietnamese children. J. Clin. Microbiol. 52(5), 1366-1374 (2014).
44. Yazawa S, Yokobori T, Ueta G et al. Blood group substances as potential therapeutic agents for the prevention and treatment of infection with noroviruses proving novel binding patterns in human tissues. PLoS ONE 9(2), e89071 (2014).
45. Bui T, Kocher J, Li Y et al. Median infectious dose of human norovirus GII. 4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. J. Gen. Virol. 94(Pt 9), 2005-2016 (2013).
46. Taube S, Perry JW, Mcgreevy E et al. Murine noroviruses bind glycolipid and glycoprotein attachment receptors in a strain-dependent manner. J. Virol. 86(10), 5584-5593 (2012).
47. Taube S, Perry JW, Yetming K et al. Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses. J. Virol. 83(9), 4092-4101 (2009).
48. Miura T, Sano D, Suenaga A et al. Histoblood group antigen-like substances of human enteric bacteria as specific adsorbents for human noroviruses. J. Virol. 87(17), 9441-9451 (2013).
49. Jones MK, Watanabe M, Zhu S et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 346(6210), 755-759 (2014).
50. Shanker S, Czako R, Sankaran B, Atmar RL, Estes MK, Prasad BV. Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses. J. Virol. 88(11), 6168-6180 (2014).
51. Lopman BA, Trivedi T, Vicuna Y et al. Norovirus infection and disease in an ecuadorian birth cohort: association of certain norovirus genotypes with host FUT2 secretor status. J. Infect. Dis. 211(11 ), 1813-1821 (2014).
52. Currier RL, Payne DC, Staat MA et al. Innate susceptibility to norovirus infections influenced by FUT2 genotype in a United States pediatric population. Clin. Infect. Dis. 60(11), 1631-1638 (2015).
53. Lindesmith LC, Beltramello M, Donaldson EF et al. Immunogenetic mechanisms driving norovirus GII. 4 antigenic variation. PLoS Pathog. 8(5), e1002705 (2012).
54. Debbink K, Lindesmith LC, Ferris MT et al. Within-host evolution results in antigenically distinct GII. 4 noroviruses. J. Virol. 88(13), 7244-7255 (2014).
55. Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg. Infect. Dis. 19(8), 1260-1267 (2013).
56. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med. 297(2), 86-89 (1977).
57. Karst SM, Wobus CE, Goodfellow IG, Green KY, Virgin HW. Advances in norovirus biology. Cell Host Microbe. 15(6), 668-680 (2014).
58. Karst SM, Zhu S, Goodfellow IG. The molecular pathology of noroviruses. J. Pathol. 235(2), 206-216 (2015).
59. Reeck A, Kavanagh O, Estes MK et al. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 202(8), 1212-1218 (2010).
60. Czako R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin. Vaccine Immunol. 19(2), 284-287 (2012).
61. Ramani S, Neill FH, Opekun AR et al. Mucosal and cellular immune responses to Norwalk virus. J. Infect. Dis. pii: jiv053 (2015) (Epub ahead of print).
62. Lochridge VP, Jutila KL, Graff JW, Hardy ME. Epitopes in the p2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J. Gen. Virol. 86(Pt 10), 2799-2806 (2005).
63. Lindesmith LC, Donaldson EF, Beltramello M et al. Particle conformation regulates antibody access to a conserved GII. 4 norovirus blockade epitope. J. Virol. 88(16), 8826-8842 (2014).
64. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HWT. STAT1-dependent innate immunity to a Norwalk-like virus. Science 299(5612), 1575-1578 (2003).
65. Chachu KA, Strong DW, Lobue AD, Wobus CE, Baric RS, Virgin HWT. Antibody is critical for the clearance of murine norovirus infection. J. Virol. 82(13), 6610-6617 (2008).
66. Lindesmith LC, Donaldson E, Leon J et al. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J. Virol. 84(4), 1800-1815 (2010).
67. Jung K, Scheuer KA, Zhang Z, Wang Q, Saif LJ. Pathogenesis of GIII. 2 bovine norovirus, CV186-oh/00/us strain in gnotobiotic calves. Vet. Microbiol. 168(1), 202-207 (2014).
68. Waugh E, Chen A, Baird MA, Brown CM, Ward VK. Characterization of the chemokine response of RAW264. 7 cells to infection by murine norovirus. Virus Res. 181, 27-34 (2014).
69. Tomov VT, Osborne LC, Dolfi DV et al. Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses. J. Virol. 87(12), 7015-7031 (2013).
70. Zhu S, Regev D, Watanabe M et al. Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains. PLoS Pathog. 9(9), e1003592 (2013).
71. Kocher J, Bui T, Giri-Rachman E et al. Intranasal P particle vaccine provided partial cross-variant protection against human GII. 4 norovirus diarrhea in gnotobiotic pigs. J. Virol. 88(17), 9728-9743 (2014).
72. Wyatt RG, Dolin R, Blacklow NR et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J. Infect. Dis. 129(6), 709-714 (1974).
73. Richardson C, Bargatze RF, Goodwin R, Mendelman PM. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev. Vaccines 12(2), 155-167 (2013).
74. Atmar RL, Estes MK. Norovirus vaccine development: next steps. Expert Rev. Vaccines 11(9), 1023-1025 (2012).
75. Debbink K, Lindesmith LC, Baric RS. The state of norovirus vaccines. Clin. Infect. Dis. 58(12), 1746-1752 (2014).
76. Atmar RL, Bernstein DI, Harro CD et al. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365(23), 2178-2187 (2011).
77. El-Kamary SS, Pasetti MF, Mendelman PM et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202(11), 1649-1658 (2010).
78. Ramirez K, Wahid R, Richardson C et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin. Immunol. 144(2), 98-108 (2012).
79. Bernstein DI, Atmar RL, Lyon GM et al. Norovirus vaccine against experimental human GII. 4 virus illness: a challenge study in healthy adults. J. Infect. Dis. 211(6), 870-878 (2015).
80. Treanor JJ, Atmar RL, Frey SE et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate-reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J. Infect. Dis. 210(11), 1763-1771 (2014).
81. Tan M, Jiang X. Vaccine against norovirus. Hum. Vaccin. Immunother. 10(6), 1449-1456 (2014).
82. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66(11), 6527-6532 (1992).
83. Xia M, Farkas T, Jiang X. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J. Med. Virol. 79(1), 74-83 (2007).
84. Lai H, Chen Q. Bioprocessing of plantderived virus-like particles of Norwalk virus capsid protein under current good manufacture practice regulations. Plant Cell Rep. 31(3), 573-584 (2012).
85. Cheetham S, Souza M, Mcgregor R, Meulia T, Wang Q, Saif LJ. Binding patterns of human norovirus-like particles to buccal and intestinal tissues of gnotobiotic pigs in relation to A/H histo-blood group antigen expression. J. Virol. 81(7), 3535-3544 (2007).
86. Huang P, Farkas T, Marionneau S et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J. Infect. Dis. 188(1), 19-31 (2003).
87. Huang P, Farkas T, Zhong W et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J. Virol. 79(11), 6714-6722 (2005).
88. Nilsson J, Rydell GE, Le Pendu J, Larson G. Norwalk virus-like particles bind specifically to A, H and difucosylated Lewis but not to B histo-blood group active glycosphingolipids. Glycoconj. J. 26(9), 1171-1180 (2009).
89. Nice TJ, Baldridge MT, Mccune BT et al. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347(6219), 269-273 (2015).
90. Tan M, Jiang X. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond. ) 7(6), 889-897 (2012).
91. Taube S, Kolawole AO, Hohne M et al. A mouse model for human norovirus. MBio. 4(4), pii: e00450-13 (2013).
92. Souza M, Azevedo MS, Jung K, Cheetham S, Saif LJ. Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II. 4-HS66 strain of human norovirus. J. Virol. 82(4), 1777-1786 (2008).
93. Parra GI, Bok K, Taylor R et al. Immunogenicity and specificity of norovirus consensus GII. 4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30(24), 3580-3586 (2012).
94. Tamminen K, Huhti L, Koho T et al. A comparison of immunogenicity of norovirus GII. 4 virus-like particles and p-particles. Immunology 135(1), 89-99 (2012).
95. Debbink K, Lindesmith LC, Donaldson EF, Swanstrom J, Baric RS. Chimeric GII. 4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses. J. Virol. 88(13), 7256-7266 (2014).
96. Lindesmith LC, Donaldson EF, Lobue AD et al. Mechanisms of GII. 4 norovirus persistence in human populations. PLoS Med. 5(2), e31 (2008).
97. Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 29(45), 8126-8133 (2011).
98. Lopman B, Simmons K, Gambhir M, Vinje J, Parashar U. Epidemiologic implications of asymptomatic reinfection: a mathematical modeling study of norovirus. Am. J. Epidemiol. 179(4), 507-512 (2014).
99. Ma Y, Duan Y, Wei Y et al. Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector. J. Virol. 88(9), 5122-5137 (2014).
100. Ma Y, Li J. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J. Virol. 85(6), 2942-2952 (2011).
101. Tan M, Fang P, Chachiyo T et al. Noroviral P particle: structure, function and applications in virus-host interaction. Virology 382(1), 115-123 (2008).
102. Kim SH, Chen S, Jiang X, Green KY, Samal SK. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice. J. Virol. 88(17), 9718-9727 (2014).
103. Harrington PR, Yount B, Johnston RE, Davis N, Moe C, Baric RS. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J. Virol. 76(2), 730-742 (2002).
104. Tan M, Huang P, Meller J, Zhong W, Farkas T, Jiang X. Mutations within the p2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J. Virol. 77(23), 12562-12571 (2003).
105. Fang H, Tan M, Xia M, Wang L, Jiang X. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLoS ONE 8(4), e63269 (2013).
106. Woodward JM, Gkrania-Klotsas E, Cordero-Ng AY et al. The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am. J. Gastroenterol. 110(2), 320-327 (2015).
107. Tan M, Jiang X. The formation of P particle increased immunogenicity of norovirus P protein. Immunology 136(1), 28-29 (2012).
108. Tan M, Jiang X. The P domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J. Virol. 79(22), 14017-14030 (2005).
109. Souza M, Costantini V, Azevedo MS, Saif LJ. A human norovirus-like particle vaccine adjuvanted with iscom or mlt induces cytokine and antibody responses and protection to the homologous GII. 4 human norovirus in a gnotobiotic pig disease model. Vaccine 25(50), 8448-8459 (2007).
110. Bok K, Parra GI, Mitra T et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl Acad. Sci. USA 108(1), 325-330 (2011).
111. Guo L, Wang J, Zhou H et al. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. Vaccine 26(4), 460-468 (2008).
112. Tan M, Fang PA, Xia M, Chachiyo T, Jiang W, Jiang X. Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles. Virology 410(2), 345-352 (2011).
113. Tan M, Huang P, Xia M et al. Norovirus P particle, a novel platform for vaccine development and antibody production. J. Virol. 85(2), 753-764 (2011).
114. Stanley M. HPV: immune response to infection and vaccination. Infect. Agent Cancer 5, 19 (2010).
115. Wang L, Huang P, Fang H et al. Polyvalent complexes for vaccine development. Biomaterials 34(18), 4480-4492 (2013).
116. Wang L, Cao D, Wei C, Meng XJ, Jiang X, Tan M. A dual vaccine candidate against norovirus and hepatitis e virus. Vaccine 32(4), 445-452 (2014).
117. Wang L, Xia M, Huang P et al. Branchedlinear and agglomerate protein polymers as vaccine platforms. Biomaterials 35(29), 8427-8438 (2014).
118. Rocha-Pereira J, Neyts J, Jochmans D. Norovirus: targets and tools in antiviral drug discovery. Biochem. Pharmacol. 91(1), 1-11 (2014).
119. Galasiti Kankanamalage AC, Kim Y, Weerawarna PM et al. Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies. J. Med. Chem. 58(7), 3144-3155 (2015).
120. Takahashi D, Kim Y, Lovell S, Prakash O, Groutas WC, Chang KO. Structural and inhibitor studies of norovirus 3C-like proteases. Virus Res. 178(2), 437-444 (2013).
121. Croci R, Tarantino D, Milani M et al. PPNDS inhibits murine norovirus RNAdependent RNA-polymerase mimicking two RNA stacking bases. FEBS Lett. 588(9), 1720-1725 (2014).
122. Tarantino D, Pezzullo M, Mastrangelo E et al. Naphthalene-sulfonate inhibitors of human norovirus RNA-dependent RNApolymerase. Antiviral Res. 102, 23-28 (2014).
123. Eltahla AA, Lim KL, Eden JS, Kelly AG, Mackenzie JM, White PA. Nonnucleoside inhibitors of norovirus RNA polymerase: scaffolds for rational drug design. Antimicrob. Agents Chemother. 58(6), 3115-3123 (2014).
124. Gonzalez-Hernandez MJ, Pal A, Gyan KE et al. Chemical derivatives of a small molecule deubiquitinase inhibitor have antiviral activity against several RNA viruses. PLoS ONE 9(4), e94491 (2014).
125. Arias A, Thorne L, Goodfellow I. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife 3, e03679 (2014).
126. Rocha-Pereira J, Jochmans D, Debing Y, Verbeken E, Nascimento MS, Neyts J. The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirusinduced diarrhea and mortality in a mouse model. J. Virol. 87(21), 11798-11805 (2013).
127. Rocha-Pereira J, Jochmans D, Neyts J. Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus. J. Antimicrob. Chemother. 70(1), 190-197 (2015).
128. Croci R, Pezzullo M, Tarantino D et al. Structural bases of norovirus RNA dependent RNA polymerase inhibition by novel suramin-related compounds. PLoS ONE 9(3), e91765 (2014).
129. Jung K, Wang Q, Kim Y et al. The effects of simvastatin or interferon-alpha on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals. PLoS ONE 7(7), e41619 (2012).